Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis

  Free Subscription


16.09.2019

1 Arch Virol
1 Cancer
8 Clin Infect Dis
1 Eur J Gastroenterol Hepatol
1 Hepatology
4 J Hepatol
3 J Infect Dis
1 J Med Virol
12 J Viral Hepat
1 J Virol
1 Lancet Gastroenterol Hepatol
1 PLoS Med
2 PLoS One
1 PLoS Pathog
1 Transplantation
2 Vaccine
1 Z Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Arch Virol

  1. YANG JJ, Fan HZ, Tian T, Wu MP, et al
    Impact of CYP2R1, CYP27A1 and CYP27B1 genetic polymorphisms controlling vitamin D metabolism on susceptibility to hepatitis C virus infection in a high-risk Chinese population.
    Arch Virol. 2019 Sep 13. pii: 10.1007/s00705-019-04378.
    PubMed     Text format     Abstract available


    Cancer

  2. YI SW, Choi JS, Yi JJ, Lee YH, et al
    Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31406.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  3. MOCROFT A, Lundgren J, Gerstoft J, Rasmussen LD, et al
    Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment.
    Clin Infect Dis. 2019 Jul 2. pii: 5527213. doi: 10.1093.
    PubMed     Text format     Abstract available

  4. KUSHNER T, Chen Z, Tressler S, Kaufman H, et al
    Trends in Hepatitis B Infection and Immunity among Women of Childbearing Age in the United States.
    Clin Infect Dis. 2019 Aug 26. pii: 5554743. doi: 10.1093.
    PubMed     Text format     Abstract available

  5. MERAT S
    SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
    Clin Infect Dis. 2019 Jul 10. pii: 5531032. doi: 10.1093.
    PubMed     Text format     Abstract available

  6. MCMAHON BJ, Townshend-Bulson L, Homan C, Gounder P, et al
    Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High Linkage to Care.
    Clin Infect Dis. 2019 Aug 28. pii: 5555891. doi: 10.1093.
    PubMed     Text format     Abstract available

  7. KOIBUCHI T, Koga M, Kikuchi T, Horikomi T, et al
    Prevalence of hepatitis A immunity and decision-tree analysis among HIV-infected men who have sex with men, in Tokyo.
    Clin Infect Dis. 2019 Aug 26. pii: 5554745. doi: 10.1093.
    PubMed     Text format     Abstract available

  8. SAEED S, Strumpf E, Moodie EEM, Wong L, et al
    Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with HIV.
    Clin Infect Dis. 2019 Aug 28. pii: 5555890. doi: 10.1093.
    PubMed     Text format     Abstract available

  9. NORTON BL, Litwin AH
    A Call to Action: HCV Treatment of People Who Inject Drugs in the United States.
    Clin Infect Dis. 2019 Sep 12. pii: 5568312. doi: 10.1093.
    PubMed     Text format    

  10. GRAF C, Mucke MM, Dultz G, Peiffer KH, et al
    Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
    Clin Infect Dis. 2019 Sep 12. pii: 5568364. doi: 10.1093.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  11. CHEN PC, Chen BH, Huang CH, Jeng WJ, et al
    Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and sp
    Eur J Gastroenterol Hepatol. 2019;31:1256-1263.
    PubMed     Text format     Abstract available


    Hepatology

  12. VERNA EC, Tsapepas D, Emond JC, Brown RS Jr, et al
    Utilization of HCV-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30933.
    PubMed     Text format     Abstract available


    J Hepatol

  13. LI L, Barry V, Daffis S, Niu C, et al
    Anti-HBV Response to Toll-Like Receptor 7 Agonist GS-9620 is Associated with Intrahepatic Aggregates of T Cells and B Cells.
    J Hepatol. 2017 Dec 14. pii: S0168-8278(17)32490.
    PubMed     Text format     Abstract available

  14. LEVADA K, Guldiken N, Zhang X, Vella G, et al
    Hsp72 protects from liver injury via attenuation of hepatocellular death, oxidative stress and JNK-signaling.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30008.
    PubMed     Text format     Abstract available

  15. WONG GL, Wong VW, Yuen BW, Tse YK, et al
    Risk of hepatitis B surface antigen seroreversion after corticosteroid in patients with previous hepatitis B virus exposure.
    J Hepatol. 2019 Sep 6. pii: S0168-8278(19)30516.
    PubMed     Text format     Abstract available

  16. LING SC, Mogul D
    Treatment of infants with hepatitis B virus: A window of opportunity?
    J Hepatol. 2019 Sep 7. pii: S0168-8278(19)30473.
    PubMed     Text format    


    J Infect Dis

  17. YE J, Wu Y, Li M, Gong X, et al
    Keratin 8 mutations were associated with susceptibility to chronic hepatitis B and related progression.
    J Infect Dis. 2019 Sep 13. pii: 5568471. doi: 10.1093.
    PubMed     Text format     Abstract available

  18. TRESSLER SR, Kushner T, Bhandari R
    Factors Associated with Hepatitis B Exposure among People who Report Using Methamphetamine: NHANES 2009-2016.
    J Infect Dis. 2019 Aug 30. pii: 5556601. doi: 10.1093.
    PubMed     Text format     Abstract available

  19. EMMANUEL B, El-Kamary SS, Magder LS, Stafford KA, et al
    Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-DeltaG and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy.
    J Infect Dis. 2019 Aug 26. pii: 5554606. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Med Virol

  20. HAO QQ, Wang QH, Xia W, Qian HZ, et al
    Circulating miRNA Expression Profile and Bioinformatics Analysis in Patients with Occult Hepatitis B Virus Infection.
    J Med Virol. 2019 Sep 12. doi: 10.1002/jmv.25594.
    PubMed     Text format     Abstract available


    J Viral Hepat

  21. MAK JSM, Lao TT, Leung MBW, Chung CHS, et al
    Ovarian HBV replication following ovulation induction in female Hepatitis B carriers undergoing IVF treatment: a prospective observational study.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13210.
    PubMed     Text format     Abstract available

  22. SAINZ T, Fernandez McPhee C, Dominguez-Rodriguez S, Hierro L, et al
    Longitudinal Evolution Of Vertically HIV/HCV Coinfected Vs HCV Monoinfected Children.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13206.
    PubMed     Text format     Abstract available

  23. MILLER LS, Millman AJ, Lom J, Osinubi A, et al
    Defining the Hepatitis C Cure Cascade in an Urban Health System Using the Electronic Health Record.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13199.
    PubMed     Text format     Abstract available

  24. CHO KS, Sohn W, Lee YC, Chi SA, et al
    Use of cyclooygenase inhibitor and the risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nested case-control study using a nationwide population-based data.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13201.
    PubMed     Text format     Abstract available

  25. IRELAND G, Simmons R, Hickman M, Harris R, et al
    Data linkage to monitor hepatitis C-associated end-stage liver disease and hepatocellular carcinoma inpatient stays in England.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13203.
    PubMed     Text format     Abstract available

  26. ARSLAN F
    Cytomegalovirus and hepatitis after bone marrow transplantation.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13200.
    PubMed     Text format     Abstract available

  27. LAURSEN TL, Siggaard CB, Kazankov K, Sandahl TD, et al
    Time-dependent improvement of liver inflammation, fibrosis, and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13204.
    PubMed     Text format     Abstract available

  28. HE WQ, Duong MC, Gidding H, MacLachlan J, et al
    Trends in chronic hepatitis B prevalence in Australian women by country of birth, 2000 to 2016.
    J Viral Hepat. 2019 Sep 9. doi: 10.1111/jvh.13202.
    PubMed     Text format     Abstract available

  29. VAN SANTEN DK, Boyd A, Bruisten S, Sonder GJ, et al
    Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high-risk groups.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13205.
    PubMed     Text format     Abstract available

  30. BUCHANAN R, Cooper K, Grellier L, Khakoo SI, et al
    The testing of people with any risk factor for Hepatitis C in community pharmacies is cost effective.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13207.
    PubMed     Text format     Abstract available

  31. RAO H, Song G, Li G, Yang Y, et al
    Safety and efficacy of coblopasvir and sofosbuvir in patients with genotype 1, 2, 3, and 6 HCV infections without or with compensated cirrhosis.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13208.
    PubMed     Text format     Abstract available

  32. BAKAROZI M, Mavropoulos A, Bogdanos DP, Dalekos GN, et al
    Title: p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13209.
    PubMed     Text format     Abstract available


    J Virol

  33. TSAI CN, Pan TC, Chiang CH, Yu CC, et al
    Serine 229 balances the hepatitis C virus nonstructural protein NS5A between hypo- and hyper-phosphorylated states.
    J Virol. 2019 Sep 11. pii: JVI.01028-19. doi: 10.1128/JVI.01028.
    PubMed     Text format     Abstract available


    Lancet Gastroenterol Hepatol

  34. FURLOW B
    Widespread hepatitis A outbreaks in the USA strain public health agencies.
    Lancet Gastroenterol Hepatol. 2019;4:755-756.
    PubMed     Text format    


    PLoS Med

  35. LEE YC, Wang JL, Dong YH, Chen HC, et al
    Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: A cohort study.
    PLoS Med. 2019;16:e1002894.
    PubMed     Text format     Abstract available


    PLoS One

  36. REZAEI N, Asadi-Lari M, Sheidaei A, Khademi S, et al
    Liver cirrhosis mortality at national and provincial levels in Iran between 1990 and 2015: A meta regression analysis.
    PLoS One. 2019;14:e0198449.
    PubMed     Text format     Abstract available

  37. CROWLEY D, Cullen W, Lambert JS, Van Hout MC, et al
    Competing priorities and second chances - A qualitative exploration of prisoners' journeys through the Hepatitis C continuum of care.
    PLoS One. 2019;14:e0222186.
    PubMed     Text format     Abstract available


    PLoS Pathog

  38. LEE JS, Tabata K, Twu WI, Rahman SM, et al
    RACK1 mediates rewiring of intracellular networks induced by hepatitis C virus infection.
    PLoS Pathog. 2019;15:e1008021.
    PubMed     Text format     Abstract available


    Transplantation

  39. CANNON RM, Locke JE, Orandi BJ, Anderson DJ, et al
    Impact of donor hepatitis C virus on kidney transplant outcomes for hepatitis C positive recipients in the direct acting antiviral era: time to revise the kidney donor risk index?
    Transplantation. 2019 Sep 9. doi: 10.1097/TP.0000000000002949.
    PubMed     Text format     Abstract available


    Vaccine

  40. LOPES JLS, Oliveira DCA, Utescher CLA, Quintilio W, et al
    Antigenic and physicochemical characterization of Hepatitis B surface protein under extreme temperature and pH conditions.
    Vaccine. 2019 Sep 10. pii: S0264-410X(19)31193.
    PubMed     Text format     Abstract available

  41. WANG LY, Chen CF, Wu TW, Lai SK, et al
    Response to hepatitis B vaccination is co-determined by HLA-DPA1 and -DPB1.
    Vaccine. 2019 Sep 9. pii: S0264-410X(19)31186.
    PubMed     Text format     Abstract available


    Z Gastroenterol

  42. BENGSCH B, Thimme R
    Success of immune checkpoint blockade therapies - mechanisms and implications for hepatology.
    Z Gastroenterol. 2019;57:74-86.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: